• About Us
    • Contact Us
    • Login
    • ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • #GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
About Us Contact Us Login ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • 0 CME Hours
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • #GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
#Grand Rounds

Mammography or Improved Treatment: Which is More Strongly Associated with a Decline in Breast Cancer Mortality?

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE:

  • Burton and Stevenson (JAMA Network Open, 2020) assessed the relative mortality reductions associated with mammography and adjuvant therapy among women with early breast cancer

METHODS:

  • Secondary analysis of cross-sectional studies
    • Victoria, Australia from January 1982 to December 2013
  • Participants
    • Invasive breast cancer
  • Data
    • Population-based surveys of breast cancer treatment: From 1986 to 1999
    • Clinical information on breast cancer incidence, mortality, and TNM stage at diagnosis: From 1986 to 2013
    • Mammography data (BreastScreen Program): From 1992 to 2007
  • Exposures
    • Participation in mammography screening program
    • Receipt of adjuvant therapy after surgery for EBC
  • Study design
    • Breast cancer incidence and mortality data were analyzed for all women with registered invasive breast cancer
    • Breast cancer treatment and screening data were analyzed additionally for the groups of surveyed women
    • Data were analyzed for
      • Associations between crude breast cancer mortality trends and uptake of adjuvant therapy
      • Downstaging by mammographic screening (lowering of stage)

RESULTS:

  • Total of 76,630 women with breast cancer from January 1, 1982, to December 31, 2013
  • Increase in breast cancer mortality from 1982 to 1994
    • 1982: 31.6 cases per 100,000 women
    • 1999: 34.3 per 100,000 women in 1994
  • Significant declining trend in breast cancer mortality from 1994 to 2013
    • 2013: 23.9 per 100,000 women
    • Annual percentage change −1.3% (95% CI, −1.6% to −0.9%)
  • By 1994, 74% of all women early breast cancer were receiving adjuvant endocrine therapy
    • Premenopausal: 72%
    • Postmenopausal: 29%
  • Crude incidence of advanced-stage breast cancer almost doubled from 1986 to 2013
    • 1986: 12.2 per 100,000 women
    • 2013: 23.9 per 100,000 women

CONCLUSION:

  • Mammography did not lead to downstaging of breast cancer from advanced to early
    • Benefit to population mortality is lacking
  • The decline in Victorian breast cancer mortality can be attributed to adjuvant therapy uptake and not mammography
  • The authors conclude that

We found that adjuvant therapy accounted for the observed 30% mortality decline; given this finding, we propose that BreastScreen should be terminated.

Continuous measurement of breast cancer stages at diagnosis, all-cause and breast cancer–specific mortality, and adjuvant therapy uptake should be mandatory in monitoring and evaluating mammographic screening program

Learn More – Primary Sources:

Assessment of Breast Cancer Mortality Trends Associated With Mammographic Screening and Adjuvant Therapy From 1986 to 2013 in the State of Victoria, Australia

Now You Can Get ObG Clinical Research Summaries Direct to Your Phone, with ObGFirst

ObGFirst® – Try It Free! »

image_pdfFavoriteLoadingFavorite
< Previous
All #Grand Rounds Posts
Next >

Related ObG Topics:

Mammography Guidelines for Average-Risk Women
A Breast Cancer Diagnosis in the Interval Between Mammograms: Who is at Risk?
For Women with A Personal History of Breast Cancer: Mammography or Breast MRI?
How Effective Is Mammography in Reducing the Number of Advanced Breast Cancer Diagnoses?

Sections

  • COVID-19
  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • #Grand Rounds
  • My Bookshelf
  • Now@ObG
  • Media

ObG Library

  • Hysteroscopy
  • Fertility
  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Get Guideline Alerts Direct to Your Phone
Try ObGFirst Free!

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Log In to ObG First

Please log in to access OBGFirst and the 2T Ultrasound Atlas

Password Trouble?

Sign Up for ObGFirst

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!

ObG First Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site